Phaseline

Targets › TRPM7

TRPM7 (Transient receptor potential cation channel subfamily M member 7): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 2; Other; next expected readout Dec 2026.

Bifunctional protein that combines an ion channel with an intrinsic kinase domain, enabling it to modulate cellular functions either by conducting ions through the pore or by phosphorylating downstream proteins via its kinase domain. The channel is highly permeable to divalent cations, specifically calcium (Ca2+), magnesium (Mg2+) and zinc (Zn2+) and mediates their influx. (UniProt, Q96QT4)

Open in Phaseline: the race on TRPM7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of California, DavisMagnesium Sulfate
N-methyl-D-aspartate (NMDA) receptor antagonist; modulates ion channels involved in pain s
TRPM7Phase 4TraumaDec 2026
Tanta UniversityMagnesium sulfate
NMDA receptor antagonist and ion channel modulator; enhances local anesthetic effect
TRPM7Phase 2Pain Score Reduction–

Conditions

Trauma (1) Pain Score Reduction (1)

Modalities

small molecule (2)

Companies

University of California, Davis (1) Tanta University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.